Enovis (NYSE:ENOV – Get Rating) updated its FY 2022 earnings guidance on Tuesday. The company provided EPS guidance of $2.20-$2.40 for the period, compared to the consensus EPS estimate of $2.30. The company issued revenue guidance of -.
Several analysts have recently commented on ENOV shares. Robert W. Baird lowered their price objective on Enovis from $79.00 to $73.00 in a research note on Wednesday, May 11th. Zacks Investment Research lowered shares of Enovis from a hold rating to a sell rating in a research note on Monday, May 2nd.
Enovis stock opened at $63.44 on Tuesday. Enovis has a 52 week low of $59.15 and a 52 week high of $164.01. The company has a market cap of $3.43 billion, a price-to-earnings ratio of 48.06, a PEG ratio of 0.63 and a beta of 2.20. The company has a current ratio of 1.62, a quick ratio of 1.03 and a debt-to-equity ratio of 0.35.
Enovis Company Profile (Get Rating)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.
- Get a free copy of the StockNews.com research report on Enovis (ENOV)
- Etsy Buy!: Why Etsy Stock is Making a Crafty Comeback
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- Option Care Health Stock is Making a Healthy Pullback
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
- Warby Parker Stock Is A High-Probability Candidate For A Short-Squeeze
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.